Research Update

RNS Number:2037M
Ardana PLC
12 May 2005


ARDANA ANNOUNCES SUCCESSFUL RESULTS IN SECOND PHASE II STUDY OF TEVERELIX LA IN
                                PROSTATE CANCER


Edinburgh, UK, 12 May 2005;  Ardana plc (LSE:ARA) the emerging pharmaceutical
company focused on improving human reproductive health, today announces
successful results of a second Phase II study of the Gonadotrophin Releasing
Antagonist (GnRH), Teverelix LA (Long Acting), in patients with advanced
prostate cancer.

The progression of prostate cancer is usually driven by male sex hormones
(androgens) such as testosterone.  It is widely accepted that reducing levels of
these hormones in advanced disease can help slow the growth of the cancer and
prolong survival.  The production of testosterone can be reduced either
surgically, with the removal of the testicles, or through drugs that affect
production of testosterone. This study confirmed that Teverelix LA can attain
and maintain suppression of testosterone to castration levels in patients with
advanced prostate cancer.

In previous clinical studies Teverelix has been shown to reduce testosterone
levels rapidly to castration levels.  In this trial Teverelix LA was tested at a
lower dose and administered via a different route (intramuscularly) compared to
the first Phase II study reported on 17 February 2005.

In this second Phase II trial, 14 patients with advanced prostate cancer each
received two 90 mg doses of Teverelix LA.  Each dose was administered as a
single intramuscular injection on Day 1 and Day 8 of the study.  After the first
injection, suppression of testosterone to castration levels (